NCT02646189View on ClinicalTrials.gov

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Hepatitis B, Chronic
Interventions
DRUG

REP 2139-Ca

REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.

DRUG

Zadaxin

Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection

DRUG

Pegasys

Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.

Trial Locations (1)

1213

Farabi General Hospital, Dhaka

All Listed Sponsors
lead

Replicor Inc.

INDUSTRY

NCT02646189 - Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients | Biotech Hunter | Biotech Hunter